Literature DB >> 17158945

Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.

Jashvant D Unadkat1, Diane W Wara, Michael D Hughes, Anita A Mathias, Diane T Holland, Mary E Paul, James Connor, Sharon Huang, Bach-Yen Nguyen, D Heather Watts, Lynne M Mofenson, Elizabeth Smith, Paul Deutsch, Kathleen A Kaiser, Ruth E Tuomala.   

Abstract

Human immunodeficiency virus-infected women (n=16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17158945      PMCID： PMC1797783          DOI： 10.1128/AAC.00420-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

Authors:  E F Choo; B Leake; C Wandel; H Imamura; A J Wood; G R Wilkinson; R B Kim
Journal:  Drug Metab Dispos       Date:  2000-06       Impact factor: 3.922

2.  HIV's pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics.

Authors:  P Bean
Journal:  Am Clin Lab       Date:  2000 Nov-Dec

Review 3.  Physiologic changes in pregnancy and their effect on drug disposition.

Authors:  M C Frederiksen
Journal:  Semin Perinatol       Date:  2001-06       Impact factor: 3.300

Review 4.  Therapeutic drug monitoring in HIV infection: current status and future directions.

Authors:  David Back; Giorgio Gatti; Courtney Fletcher; Rodolphe Garaffo; Richard Haubrich; Richard Hoetelmans; Michael Kurowski; Andrew Luber; Concepta Merry; Carlo-Federico Perno
Journal:  AIDS       Date:  2002-03       Impact factor: 4.177

5.  Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.

Authors:  Timothy S Tracy; Raman Venkataramanan; Douglas D Glover; Steve N Caritis
Journal:  Am J Obstet Gynecol       Date:  2005-02       Impact factor: 8.661

6.  Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein.

Authors:  Anita A Mathias; Lillian Maggio-Price; Yurong Lai; Anshul Gupta; Jashvant D Unadkat
Journal:  J Pharmacol Exp Ther       Date:  2005-11-17       Impact factor: 4.030

7.  Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-01-30

8.  Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

Authors:  Asda Vibhagool; Pedro Cahn; Mauro Schechter; Fiona Smaill; Luis Soto-Ramirez; Giampiero Carosi; Maria Montroni; Cristina E Pharo; Jamie C Jordan; Nicola E Thomas; Gill Pearce
Journal:  Curr Med Res Opin       Date:  2004-07       Impact factor: 2.580

9.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

Review 10.  Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view.

Authors:  Philippe Clevenbergh; Stéphane Mouly; Pierre Sellier; Esma Badsi; Jeanine Cervoni; Valérie Vincent; Hervé Trout; Jean-François Bergmann
Journal:  Curr HIV Res       Date:  2004-10       Impact factor: 1.581
View more
  31 in total

1.  Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

Authors:  Mark Mirochnick; Brookie M Best; Alice M Stek; Edmund V Capparelli; Chengcheng Hu; Sandra K Burchett; Steven S Rossi; Elizabeth Hawkins; Michael Basar; Elizabeth Smith; Jennifer S Read
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04-15       Impact factor: 3.731

2.  Implications of gender and pregnancy for antiretroviral drug dosing.

Authors:  Brookie M Best; Edmund V Capparelli
Journal:  Curr Opin HIV AIDS       Date:  2008-05       Impact factor: 4.283

3.  Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.

Authors:  Mohammed Lamorde; Pauline Byakika-Kibwika; Violet Okaba-Kayom; John P Flaherty; Marta Boffito; Rhoda Namakula; Mairin Ryan; Clemensia Nakabiito; David J Back; Saye Khoo; Concepta Merry; Kimberly K Scarsi
Journal:  J Acquir Immune Defic Syndr       Date:  2010-11       Impact factor: 3.731

4.  Down-regulation of brush border efflux transporter expression in the kidneys of pregnant mice.

Authors:  Lindsay L Yacovino; Christopher J Gibson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2012-08-15       Impact factor: 3.922

Review 5.  Pharmacogenetics and individualizing drug treatment during pregnancy.

Authors:  David M Haas
Journal:  Pharmacogenomics       Date:  2014-01       Impact factor: 2.533

6.  Validation of a sensitive LC-MS assay for quantification of glyburide and its metabolite 4-transhydroxy glyburide in plasma and urine: an OPRU Network study.

Authors:  Suresh Babu Naraharisetti; Brian J Kirby; Mary F Hebert; Thomas R Easterling; Jashvant D Unadkat
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-10-22       Impact factor: 3.205

7.  As in humans, pregnancy increases the clearance of the protease inhibitor nelfinavir in the nonhuman primate Macaca nemestrina.

Authors:  Huixia Zhang; Xiaohui Wu; Francisco Chung; Suresh Babu Naraharisetti; Dale Whittington; Ahmad Mirfazaelian; Jashvant D Unadkat
Journal:  J Pharmacol Exp Ther       Date:  2009-03-17       Impact factor: 4.030

Review 8.  Antiretroviral medications during pregnancy for therapy or prophylaxis.

Authors:  Alice Marie Stek
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

Review 9.  Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.

Authors:  Matthieu Roustit; Malik Jlaiel; Pascale Leclercq; Françoise Stanke-Labesque
Journal:  Br J Clin Pharmacol       Date:  2008-05-15       Impact factor: 4.335

10.  Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS.

Authors:  Xing Zhang; Daria I Vernikovskaya; Xiaoming Wang; Tatiana N Nanovskaya; Maged Costantine; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Biomed Chromatogr       Date:  2015-09-11       Impact factor: 1.902
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.